Erratum to “Efficacy of combined BRAF-MEK inhibitor second-line therapy in patients with non-resectable or metastatic BRAFV600-positive melanoma after prior immunotherapy: A retrospective EUMelaReg multicenter study” [EJC Skin Cancer 4 (2026) 100773]
Eva Ellebaek(Copenhagen University Hospital), Dirk Schadendorf(Essen University Hospital), Christoffer Gebhardt(Universität Hamburg), Anna Mariuk-Jarema(National Institute of Oncology), Michael Weichenthal(Christian-Albrechts-Universität zu Kiel), Marco Donia(University of Copenhagen), Gergana Shalamanova-Deleva(Medical University Plovdiv), Christina H. Ruhlmann(University of Southern Denmark), Rasmus Blechingberg Friis(Aarhus University Hospital), Dimitriοs Ziogas(National and Kapodistrian University of Athens), Iva Gavrilova(University Hospital St. Ivan Rilski), Inge Marie Svane(Copenhagen University Hospital), Viktor Šabarić(University Hospital Centre Zagreb), Dimitra Stefanou(National and Kapodistrian University of Athens), Margarita Majem(Chinese Academy of Medical Sciences & Peking Union Medical College), Alfonso Berrocal(Hospital General Universitario De Valencia), Ainara Soria(Hospital Universitario Ramón y Cajal), Amalia Anastasopoulou(National and Kapodistrian University of Athens), Igor Stojkovski(University Clinic of Traumatology), Luisa Piccin(University of Naples Federico II), Alessandro Marco Minisini, Helen Gogas(National and Kapodistrian University of Athens), Berna C. Özdemir(University Hospital of Bern), B. Dujović(Military Medical Academy), Lourdes Gutiérrez(Research Institute Hospital 12 de Octubre), Ronnie Shapira, Tomislav Duvančić(Sisters of Charity Hospital), Alexander Gerasimov(University Hospital St. Ivan Rilski), Ahmed Kontilev(Tokuda Hospital), Amina Jalovčić Suljeviić(Clinical Center University of Sarajevo), Shaked Lev-Ari, Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Patrick Terheyden(University of Lübeck), Lars Bastholt(Odense University Hospital), Imke von Wasielewski(Medizinische Hochschule Hannover), Henrik Schmidt(Aarhus University Hospital), Jochen Utikal(German Cancer Research Center), Reinhard Dummer(University Hospital Zurich), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Nethanel Asher(Rabin Medical Center), Selma Ugurel(Klinikum Bielefeld), John Haanen(The Netherlands Cancer Institute), Joanna Mangana(University Hospital Zurich), Claudia Pföhler(Saarland University), Axel Hauschild(Christian-Albrechts-Universität zu Kiel), Paweł Teterycz(National Institute of Oncology), Friedegund Meier(University Hospital Carl Gustav Carus), Rudolf Herbst(Helios Klinikum Erfurt)
Cited by 0
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k